Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine plus afatinib vs gemcitabine alone in metastatic pancreatic cancer
2011-004063-77Phase 2Completed
- Sponsor
- LMU Klinikum
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in pancreatic adenocarcinoma (PDAC) comparing Afatinib + gemcitabine with Gemcitabine alone (2 arms). Primary endpoint: Overall survival. Started Aug 2012; status: completed.
02
Drugs
afatinibgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2011-004063-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004063-77.